PDE5 inhibitors, sildenafil and vardenafil, reverse multidrug resistance by inhibiting the efflux function of multidrug resistance protein 7 (ATP-binding Cassette C10) transporter

Cancer Science

Volumn 103, Issue 8, 2012, Pages 1531-1537

  Chen, Jun Jiang ^a,b   Sun, Yue Li ^a,c   Tiwari, Amit K ^a   Xiao, Zhi Jie ^a   Sodani, Kamlesh ^a   Yang, Dong Hua ^d   Vispute, Saraubh G ^a   Jiang, Wen Qi ^c   Chen, Si Dong ^b   Chen, Zhe Sheng ^a  

^a ST JOHN'S UNIVERSITY   (United States)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^d FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 7; PACLITAXEL; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG; VARDENAFIL; VINBLASTINE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; EMBRYO; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, MULTIPLE; FLUORESCENT ANTIBODY TECHNIQUE; HEK293 CELLS; HUMANS; IMIDAZOLES; IMMUNOBLOTTING; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; PURINES; SULFONES; TRIAZINES;

EID: 84864313244     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02328.x     Document Type: Article

References (37)

1. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002; 53: 615-27.
2. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219-34.
3. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2: 48-58.
4. Gottesman MM, Ambudkar SV. Overview: ABC transporters and human disease. J Bioenerg Biomembr 2001; 33: 453-8.
5. Tiwari AK, Sodani K, Dai CL, Ashby CR Jr, Chen ZS. Revisiting the ABCs of multidrug resistance in cancer chemotherapy. Curr Pharm Biotechnol 2011; 12: 570-94.
6. Doyle LA, Yang W, Abruzzo LV et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA 1998; 95: 15665-70.
7. Maliepaard M, van Gastelen MA, de Jong LA et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 1999; 59: 4559-63.
8. Dean M, Hamon Y, Chimini G. The human ATP-binding cassette (ABC) transporter superfamily. J Lipid Res 2001; 42: 1007-17.
9. Chen ZS, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J 2011; 278: 3226-45.
10. Kruh GD, Guo Y, Hopper-Borge E, Belinsky MG, Chen ZS. ABCC10, ABCC11, and ABCC12. Pflugers Arch 2007; 453: 675-84.
11. Chen ZS, Hopper-Borge E, Belinsky MG, Shchaveleva I, Kotova E, Kruh GD. Characterization of the transport properties of human multidrug resistance protein 7 (MRP7, ABCC10). Mol Pharmacol 2003; 63: 351-8.
12. Hopper-Borge E, Chen ZS, Shchaveleva I, Belinsky MG, Kruh GD. Analysis of the drug resistance profile of multidrug resistance protein 7 (ABCC10): resistance to docetaxel. Cancer Res 2004; 64: 4927-30.
13. Bessho Y, Oguri T, Ozasa H et al. ABCC10/MRP7 is associated with vinorelbine resistance in non-small cell lung cancer. Oncol Rep 2009; 21: 263-8.
14. Oguri T, Ozasa H, Uemura T et al. MRP7/ABCC10 expression is a predictive biomarker for the resistance to paclitaxel in non-small cell lung cancer. Mol Cancer Ther 2008; 7: 1150-5.
15. Naramoto H, Uematsu T, Uchihashi T et al. Multidrug resistance-associated protein 7 expression is involved in cross-resistance to docetaxel in salivary gland adenocarcinoma cell lines. Int J Oncol 2007; 30: 393-401.
16. Hopper-Borge EA, Churchill T, Paulose C et al. Contribution of Abcc10 (Mrp7) to in vivo paclitaxel resistance as assessed in Abcc10(-/-) mice. Cancer Res 2011; 71: 3649-57.
17. Wu CP, Calcagno AM, Ambudkar SV. Reversal of ABC drug transporter-mediated multidrug resistance in cancer cells: evaluation of current strategies. Curr Mol Pharmacol 2008; 1: 93-105.
18. Shi Z, Tiwari AK, Shukla S et al. Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol 2009; 77: 781-93.
19. Shi Z, Peng XX, Kim IW et al. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance. Cancer Res 2007; 67: 11012-20.
20. Dai CL, Tiwari AK, Wu CP et al. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2. Cancer Res 2008; 68: 7905-14.
21. Tiwari AK, Sodani K, Wang SR et al. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol 2009; 78: 153-61.
22. Shi Z, Tiwari AK, Shukla S et al. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance. Cancer Res 2011; 71: 3029-41.
23. Ding PR, Tiwari AK, Ohnuma S et al. The phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of ABCB1/P-glycoprotein transporter. PLoS ONE 2011; 6: e19329.
24. Zhou Y, Hopper-Borge E, Shen T et al. Cepharanthine is a potent reversal agent for MRP7(ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2009; 77: 993-1001.
25. Kuang YH, Shen T, Chen X et al. Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance. Biochem Pharmacol 2010; 79: 154-61.
26. Shen T, Kuang YH, Ashby CR et al. Imatinib and nilotinib reverse multidrug resistance in cancer cells by inhibiting the efflux activity of the MRP7 (ABCC10). PLoS ONE 2009; 4: e7520.
27. Corbin JD, Francis SH. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction. J Androl 2003; 24: S38-41.
28. Zhu B, Strada SJ. The novel functions of cGMP-specific phosphodiesterase 5 and its inhibitors in carcinoma cells and pulmonary/cardiovascular vessels. Curr Top Med Chem 2007; 7: 437-54.
29. Sarfati M, Mateo V, Baudet S et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003; 101: 265-9.
30. Das A, Durrant D, Mitchell C et al. Sildenafil increases chemotherapeutic efficacy of doxorubicin in prostate cancer and ameliorates cardiac dysfunction. Proc Natl Acad Sci USA 2010; 107: 18202-7.
31. Black KL, Yin D, Ong JM et al. PDE5 inhibitors enhance tumor permeability and efficacy of chemotherapy in a rat brain tumor model. Brain Res 2008; 1230: 290-302.
32. Serafini P, Meckel K, Kelso M et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med 2006; 203: 2691-702.
33. Doggrell S. Do vardenafil and tadalafil have advantages over sildenafil in the treatment of erectile dysfunction? Int J Impot Res 2007; 19: 281-95.
34. Turko IV, Ballard SA, Francis SH, Corbin JD. Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 1999; 56: 124-30.
35. Saenz de Tejada I, Angulo J, Cuevas P et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res 2001; 13: 282-90.
36. Porst H. IC351 (tadalafil, Cialis): update on clinical experience. Int J Impot Res 2002; 14 (Suppl. 1): S57-64.
37. Bischoff E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004; 16 (Suppl. 1): S11-4.